Donanemab | ALZFORUM
WEBFeb 14, 2019 · Donanemab is a humanized IgG1 monoclonal antibody that binds to pyroglutamate-modified Aβ, a form of amyloid plaque in the brain. It is administered intravenously or subcutaneously, and has shown to reduce amyloid load in clinical trials, but also causes ARIA-E in some patients.
ALZFORUM | NETWORKING FOR A CURE
WEB3 days ago · AlzForum is a website that covers the latest research and news on Alzheimer's disease and related dementias. Find out about new discoveries, treatments, biomarkers, and more from experts and peers in the field.
Aduhelm - ALZFORUM
WEBJan 3, 2016 · Aduhelm (aducanumab) is a monoclonal antibody that targets amyloid plaques in the brain. It is being developed by Biogen and Eisai for the treatment of Alzheimer's disease. Learn about its background, findings, clinical trials, and …
Trontinemab - ALZFORUM
WEBMay 9, 2024 · Trontinemab is an anti-amyloid monoclonal antibody that uses a brain shuttle technology to cross the blood-brain barrier. It is being developed by Roche for Alzheimer's disease and has shown promising results in lowering brain amyloid in Phase 1 trials.
Leqembi - ALZFORUM
WEBLeqembi (BAN2401) is a humanized monoclonal antibody that targets soluble Aβ protofibrils, a form of amyloid that may be toxic to neurons. It has shown promise in slowing cognitive decline and reducing brain amyloid in Phase …
All News - ALZFORUM
WEBSep 6, 2024 · ALZFORUM is a leading online platform for Alzheimer's disease news, research, and discussion. Browse the most recent articles on topics such as biomarkers, immunotherapies, genetics, and more.
Donepezil - ALZFORUM
WEBDonepezil is a cholinesterase inhibitor approved for mild to severe Alzheimer's disease and some other dementias. Learn about its mechanism, efficacy, side effects, and clinical trials from ALZFORUM, a leading source of information on Alzheimer's research.
5xFAD (B6SJL) - ALZFORUM
WEBJan 18, 2015 · 5xFAD (B6SJL) mice express five human mutations in APP and PSEN1 genes, leading to rapid and severe amyloid pathology, synaptic loss, and neuron death. These mice are widely used to study AD-related phenotypes and have a relatively early and aggressive presentation.
ALN-APP | ALZFORUM
WEBALN-APP is a gene-silencing approach that targets the amyloid precursor protein mRNA to reduce amyloid production in the brain and cerebral blood vessels. It is being tested in a Phase 1 trial for safety and target engagement in people with early onset AD.
Simufilam - ALZFORUM
WEBApr 18, 2022 · Simufilam is a drug candidate that targets filamin, a protein involved in Aβ42-mediated tau phosphorylation and inflammation. It has shown promising results in preclinical and Phase 2 trials, and is currently in Phase 3 …
Skip to content